DBV Technologies: study recruitment completed

(CercleFinance.com) - DBV Technologies reports that it completed subject enrolment in August, a month ahead of schedule, for the Phase III VITESSE study evaluating its Viaskin Peanut patch in peanut-allergic children aged four to seven.


This 12-month study is evaluating the efficacy and safety of Viaskin Peanut in over 600 subjects (randomized 2:1), representing individuals at 86 sites in the United States, Canada, Europe, the United Kingdom and Australia.

The biopharmaceutical company points out that VITESSE is currently the largest therapeutic intervention study in peanut allergy. Initial results are expected in Q4 2025.


Copyright (c) 2024 CercleFinance.com. All rights reserved.